Literature DB >> 18395777

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

John K Chan1, Deanna Teoh, Jessica M Hu, Jacob Y Shin, Kathryn Osann, Daniel S Kapp.   

Abstract

OBJECTIVE: To compare the clinico-pathologic characteristics and survival of women with clear cell versus other epithelial ovarian cancers.
METHODS: Data were obtained from the Surveillance, Epidemiology and End Results Program between 1988 and 2001 and analyzed using Kaplan-Meier and Cox proportional hazards models.
RESULTS: Of 28,082 women with epithelial ovarian cancer, 1411 (5%) had clear cell, 13,835 (49.3%) papillary serous, 3655 (13%) endometrioid, 2711 (9.7%) mucinous, and 6470 (23%) had unspecified histologies. The median age of overall patients was 64 years; with clear cell patients presenting at younger age (55 years). The proportion of clear cell histology was significantly higher in Asians versus Whites, Blacks, and others (11.1% versus 4.8%, 3.1%, and 5.5%; p<0.001). Clear cell carcinoma is more likely to be diagnosed at early-stage (67.3%) compared to 19.2% in serous, 61.6% endometrioid, and 61.3% in mucinous carcinomas (p<0.005). Retroperitoneal lymph node metastases were found in 13.6% of serous carcinomas, 7.9% clear cell, 7.3% endometrioid, and 3.8% of mucinous (p<0.001). Adjusted for stage, the 5-year disease-specific survival of patients with clear cell carcinoma is worse compared to serous: 85.3% vs. 86.4% for stage I, 60.3% vs. 66.4% stage II, 31.5% vs. 35.0% stage III, and 17.5% vs. 22.2% for stage IV, respectively (p<0.001). On multivariate analysis, age, stage, grade, histology, and surgical treatment were independent predictors of disease-specific survival.
CONCLUSIONS: Our data suggest that women with clear cell ovarian cancer present at a younger age, are more likely to be Asian, and have a poorer prognosis compared to serous cancers.

Entities:  

Mesh:

Year:  2008        PMID: 18395777     DOI: 10.1016/j.ygyno.2008.02.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  128 in total

1.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

2.  Epigenetic determinants of ovarian clear cell carcinoma biology.

Authors:  Ken Yamaguchi; Zhiqing Huang; Noriomi Matsumura; Masaki Mandai; Takako Okamoto; Tsukasa Baba; Ikuo Konishi; Andrew Berchuck; Susan K Murphy
Journal:  Int J Cancer       Date:  2014-01-14       Impact factor: 7.396

Review 3.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

4.  Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

Authors:  Naoki Matsumoto; Takashi Umezawa; Toru Sasaki; Kuninobu Nakajima; Yukiko Kanetsuna; Hiroshi Sasaki
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

Review 5.  SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.

Authors:  Takeshi Fukumoto; Elizabeth Magno; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

6.  Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.

Authors:  Angel Chao; Chyong-Huey Lai; Tzu-Hao Wang; Shih-Ming Jung; Yun-Shien Lee; Wei-Yang Chang; Lan-Yang Yang; Fei-Chun Ku; Huei-Jean Huang; An-Shine Chao; Chin-Jung Wang; Ting-Chang Chang; Ren-Chin Wu
Journal:  J Mol Med (Berl)       Date:  2018-05-03       Impact factor: 4.599

7.  Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Authors:  Masafumi Kato; Masashi Takano; Morikazu Miyamoto; Naoki Sasaki; Tomoko Goto; Ayako Suzuki; Junko Hirata; Hidenori Sasa; Hitoshi Tsuda; Kenichi Furuya
Journal:  Mol Clin Oncol       Date:  2016-08-02

8.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

9.  The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.

Authors:  Dirk O Bauerschlag; Christian Schem; Marion T Weigel; Constantin Von Kaisenberg; Alexander Strauss; Thomas Bauknecht; Nicolai Maass; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

10.  Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US.

Authors:  Maria Theresa M Redaniel; Adriano Laudico; Maria Rica Mirasol-Lumague; Adam Gondos; Gemma Leonora Uy; Jean Ann Toral; Doris Benavides; Hermann Brenner
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.